Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 3/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.33 |
| ▸ | NPC1 | O15118 | 3/20 | 0.33 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10072773 | 0.87 | SYK (0.36) | SYKMAPK14NPC1RAB9AHTT | |
| SCHEMBL10013572 | 0.87 | GRM5 (0.36) | PTGDR2SYKALOX5APFEN1NPC1 | |
| SCHEMBL397285 | 0.86 | S1PR4 (0.36) | PTGDR2SYKNPC1RAB9AHTT | |
| SCHEMBL12451178 | 0.86 | PTGDR2 (0.34) | PTGDR2SYKALOX5APFEN1NPC1 | |
| SCHEMBL10042170 | 0.79 | MAPK14 (0.41) | SYKMAPK14FFAR1FFAR4 | |
| SCHEMBL10013569 | 0.76 | NPC1 (0.37) | SYKMAPK14NPC1RAB9AHTT | |
| SCHEMBL4568541 | 0.72 | PTGDR2 (0.35) | PTGDR2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL392605 | 0.72 | PTGDR2 (0.39) | PTGDR2FFAR1FFAR4 | |
| SCHEMBL12634560 | 0.71 | PTGDR2 (0.40) | PTGDR2ALOX5APFEN1FFAR1FFAR4 | |
| SCHEMBL10013574 | 0.68 | SGMS2 (0.34) | SYKMAPK14NPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101761-B2 | (E)-N-{3-[1-(8-fluoro-11H-10-OXA-1-AZA-dibenzo [A,D] cyclohepten-5ylidene)-propyl]-phenyl}-methanesulfonamide as glucocorticoid receptor modulator for the treatment of rheumatoid arthritis | ELI LILLY AND COMPANY (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101761-B2 | (E)-N-{3-[1-(8-fluoro-11H-10-OXA-1-AZA-dibenzo [A,D] cyclohepten-5ylidene)-propyl]-phenyl}-methanesulfonamide as glucocorticoid receptor modulator for the treatment of rheumatoid arthritis | ELI LILLY AND COMPANY (US) | 2012-01-24 | — | — | US | disclosed |
| EP-2231676-B1 | (E)-N-{3-[1-(8-FLUORO-11H-10-OXA-1-AZA-DIBENZO-[A,D]-CYCLOHEPTEN-5-YLIDENE)-PROPYL]-PHENYL }-METHYNSULFON AMIDE AS GLUCOCORTICOID RECEPTOR MODULATOR FOR THE TREATMENT OF RHEUMATOID ARTHRITIS | LILLY CO ELI (US) | 2011-08-31 | — | — | EP | disclosed |
| US-20100280062-A1 | (E)-N--METHANESULFONAMIDE AS GLUCOCORTICOID RECEPTOR MODULATOR FOR THE TREATMENT OF RHEUMATOID ARTHRITIS | ELI LILLY AND COMPANY (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100280062-A1 | (E)-N--METHANESULFONAMIDE AS GLUCOCORTICOID RECEPTOR MODULATOR FOR THE TREATMENT OF RHEUMATOID ARTHRITIS | ELI LILLY AND COMPANY (US) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280062-A1 | (E)-N--METHANESULFONAMIDE AS GLUCOCORTICOID RECEPTOR MODULATOR FOR THE TREATMENT OF RHEUMATOID ARTHRITIS | NR3C1, NR3C2, MC2R | PTGDR2 153/4885SYK 543/4885ALOX5AP 842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.